Ask about this productRelated genes to: Sdc3 antibody
- Gene:
- SDC3 NIH gene
- Name:
- syndecan 3
- Previous symbol:
- -
- Synonyms:
- N-syndecan, SYND3
- Chromosome:
- 1p35.2
- Locus Type:
- gene with protein product
- Date approved:
- 1994-05-16
- Date modifiied:
- 2014-11-19
Related products to: Sdc3 antibody
Related articles to: Sdc3 antibody
- Glioblastoma (GBM) is a highly lethal malignancy driven by glioma-initiating cells (GICs). While GICs are known to profoundly remodel tumor microenvironment (TME) to promote progression and immune evasion within the vascular niche, the specific transcriptomic reprogramming and alternative splicing events driving their evolution from neural stem cells (NSCs), and how these intrinsic cellular state changes dictate multi-cellular immunosuppressive networks and checkpoints, remain poorly understood. Unraveling these complex tumor-vascular-immune interactions is critical for identifying novel vulnerabilities and developing effective immunotherapies. - Source: PubMed
Publication date: 2026/04/23
Lin HaoLiu ChaxianChen XiZhao YingboLyu YiZhang BilongSong HaikunFan XiaominLi ShashaHe ZiqianYang HuiMao Ying - Low back pain is a leading cause of disability worldwide, and lumbar intervertebral disc degeneration (IVDD) is strongly associated with its development. Recent studies have shown that the gut microbiota (GM) and its metabolites may be involved in the occurrence and development of IVDD through the gut-disc axis. However, the key microbes mediating this process and their specific molecular mechanisms remain unclear. - Source: PubMed
Publication date: 2026/04/24
Liu HaoXie BinZhuo HangHe BowenDai JiahuiZhou ZelinShen GengyangChen BinweiTang JingjingRen HuiJiang Xiaobing - Reliable and disease-specific blood biomarkers are critically needed for Alzheimer's disease (AD), particularly in early stages when interventions are most effective. Although phosphorylated tau and neurofilament light chain (NfL) are widely used, their diagnostic specificity has been reported to decrease in elderly populations with multimorbidities. Syndecan-3 (SDC3), a heparan sulfate proteoglycan implicated in amyloid and tau aggregation, has recently emerged as a mechanistically relevant biomarker candidate. In this clinically realistic cohort study, we examined 46 participants, including 23 clinically diagnosed AD patients and 23 age-matched non-AD individuals with psychiatric and/or metabolic comorbidities. SDC3 expression was quantified in peripheral blood mononuclear cells (PBMCs), while soluble SDC3 and NfL were measured in plasma. Both PBMC-expressed and plasma SDC3 levels were elevated in AD compared with non-AD participants and showed a strong intercorrelation, whereas plasma NfL was likewise increased in AD. Individually, PBMC-SDC3, plasma SDC3, and NfL demonstrated moderate discriminatory performance. However, multivariable models integrating SDC3 (PBMC or plasma), NfL, and age achieved substantially improved discrimination (AUC > 0.8). SDC3 did not correlate with NfL, consistent with a biological signal distinct from neuroaxonal injury and reflective of peripheral immune-metabolic remodeling. Together, these findings identify SDC3 as a blood-based biomarker associated with systemic immune remodeling that complements established neuronal markers in a clinically realistic AD versus non-AD comparison. While exploratory, this study supports further investigation of SDC3 within integrated, multi-domain biomarker strategies in larger and independent cohorts. - Source: PubMed
Publication date: 2026/02/06
Hudák AnettLetoha AnnamáriaLetoha Tamás - Our earlier study demonstrated that metabolic disorders increase the expression of Syndecan-3 (Sdc-3), a heparan sulfate proteoglycan (HSPG) in erythrocytes, contributing to adhesion through the glycosaminoglycan chain. Reactive oxygen species (ROS) could be one of the factors for increased expression. This study aimed to determine whether quercetin, a bioactive antioxidant commonly found in food, could modulate Sdc-3 expression. Male Wistar rats were made dyslipidemic and diabetic, after which they were treated with quercetin at doses of 50 and 100 mg/kg body weight for a duration of 2 months. Sdc-3 expression in erythrocytes was assessed by Western blot, and erythrocyte adhesion to fibronectin was evaluated in-vitro. The quercetin-supplemented diet reduced circulating lipids, blood glucose, and MDA levels, mitigated changes in Sdc-3 expression, and decreased erythrocyte adhesion to fibronectin. These effects may be attributed to quercetin's antioxidant properties, as was seen by the positive correlation between MDA levels and Sdc-3 expression. Sdc-3 levels in erythrocytes could serve as a prognostic marker for assessing the impact of dietary compounds on complications linked to metabolic disorders. - Source: PubMed
Mallanna Smitha HonnalagereChilkunda Nandini D - Oral leukoplakia and proliferative verrucous leukoplakia represent oral potentially malignant disorders. Oral leukoplakia typically presents as solitary lesions, while proliferative verrucous leukoplakia manifests as multifocal lesions with higher malignant potential. This study aimed to investigate the genetic heterogeneity between these disorders through differential gene expression, genetic variants, and microRNA profiling to identify potential biomarkers for diagnosis and prognosis. - Source: PubMed
Publication date: 2026/03/01
Pérez-Sayáns MVieira-E-Silva F-FFernández-Rozadilla CCarracedo ÁCarlés-González SLorenzo-Pouso A-IPérez-Jardón AGándara-Vila PGarcía-García ASuárez-Peñaranda J-MBlanco-Carrión AChamorro-Petronacci C-M